Physician profile
John E Hornsby
NPI 1437142387
$6,033.25
in general payments reported to CMS, 2019-2025
18 companies · $704 in 2025
The $704 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $3,176 · 2021: $330 · 2022: $497 · 2023: $346 · 2024: $671 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,035.97 | 2020 | |
| Alcon Vision LLC | $966.09 | 2019-2025 | Precision7, Tryptyr, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $869.14 | 2022-2025 | Vyzulta, Miebo, Infuse |
| Novartis Pharmaceuticals Corporation | $196.29 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.86 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $154.29 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $154.03 | 2021-2025 | Acuvue |
| Allergan, INC. | $103.89 | 2019-2021 | |
| Dompe US, INC. | $88.75 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $81.53 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $57.90 | 2023-2024 | Cequa |
| Tearlab Corp | $34.35 | 2019 | |
| Shire North American Group INC | $33.29 | 2019 | |
| Abbvie INC. | $23.02 | 2024 | |
| Carl Zeiss Meditec, INC. | $20.51 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.86 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $19.31 | 2022 | |
| Coopervision INC. | $15.17 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hornsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.